LENZ Therapeutics: Freedom From Reading Glasses
LENZ Therapeutics is progressing rapidly with its LNZ100 for presbyopia, aiming for a 2025 U.S. launch in a market valued at ...
Fierce Pharma5h
CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy development
On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract ...
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund ...
ASX Runners of the Week: Whitehawk, OzAurum, Argent Biopharma & Galan
This content is brought to you by BULLS N’ BEARS The dead cat bounce is done and the pain returned as the ASX shed nearly 3 per cent this week. A reprieve from chat around either United States ...